

Automated cassette-based synthesis of [18F]FAPI-74 via [18F]AIF strategy for routine production in a GMP environment


Session D52 Poster #EP-523



N. Emmanuel¹, D. Goblet¹, G. Decoux¹, V. Kramer², F. Valla³, J. Agudelo³;

INTRODUCTION


Fibroblast activation protein (FAP) is overexpressed in the stroma of a variety of cancer types in humans¹. For this reason, such target is considered a very attractive imaging biomarker. Recently, small molecules labelled with PET isotopes, in particular Fluorine-18, targeting FAP have emerged^{1,2,3}. Robust automated synthesis in a GMP environment is crucial to ensure a reliable routine production of this radiopharmaceutical. In this abstract, optimized and fully automated synthesis of [18F]FAPI-74 in a disposable, cassette-based module and its quality control results will be described.



MATERIALS AND METHODS

One-pot automated synthesis has been established on a cassette-based synthesizer. The [18F]fluoride was trapped on a QMA cartridge and eluted with 500 µL of a mixture of EtOH/NaCl 0.9% (2:3) into the reactor. Subsequently, the precursor solution (72 µL of aqueous solution of FAPI-74 precursor (1 mg/mL), 300 µL MeCN, 300 µL of a 20 mM ascorbic acid solution and 10.8 µL of 10 mM AICl₃) is added to the same reactor. The fluorination was performed at 100 °C for 5 minutes. The reaction mixture was then diluted with Ascorbate buffer (pH 4.7) and purified with HLB light cartridge. [18F]FAPI-74 was eluted with 3 mL of ethanol 66%. Final formulation can be adapted by end-user depending on desired shelf-life. The overall synthesis time was 20 minutes. Quality control tests were performed including appearance, pH, radionuclidic purity, radiochemical purity, chemical purity and residual solvents.





- ¹⁸F trapping on QMA
- QMA cleaning
- 4. Precursor addition
- Labeling (5 min, 100°C)

- 7. Trapping on HLB
- 8. HLB cleaning (2x)
- 9. HLB elution

RESULTS

In this present study, automated radiosynthesis of [18F]FAPI-74 has been achieved with radiochemical yields varying from approximately 50% non-decay corrected (n.d.c) for incoming activity up to 74 GBq and >30% n.d.c. at incoming activities as high as 111 Gbg. In all cases, radiochemical purity was >95% and residual solvents below ICH Q3 limits.



CONCLUSION

Fully automated, optimized and simplified synthesis of [18F]FAPI-74 has been obtained on cassette-based module with high radiochemical and chemical purity. Ready-to use consumables will be made available to help streamline routine clinical production in a GMP setting.

REFERENCES

[1] T. Lindner, A.Loktev, F.L.Giesel, C. Kratochwil, A. Altmann and U. Haberkorn, EJNMMI Radiopharmacy and Chemistry 4 (16);2, 2019 [2] F.L. Giesel, S. Adeberg, M.Syed, T. Lindner, L. D.Jiménez-Franco, E.Mavriopoulou, F.Staudinger, E. Tonndorf-Martini, S.Regnery, S.Rieken, R. El Shafie, M. Röhrich, P. Flechsig, A. Kluge, A.Altmann, J.Debus, U.Haberkorn, C.Kratochwil; J. of Nuclear Med, 62 (2) 201-207, 2021. [3] S.Imlimthan, E.S. Moon2, H. Rathke, A.Afshar-Oromieh, F. Rösch, A. Rominger, E. Gourn; Pharmaceuticals 2021, 14, 1023, 2022.

radiopharmasolutions@iba-group.com